For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3949/ccjm.83a.15092 | DOI Listing |
Publication Analysis
Top Keywords
dual antiplatelet
16
antiplatelet therapy
16
acute coronary
8
therapy months
8
dual
4
therapy
4
therapy acute
4
coronary syndromes
4
syndromes long
4
long continue?
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!